Evidence map›Paper›PMID 33449859›Full record

ArticleJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Intraocular Injection of HyStem Hydrogel Is Tolerated Well in the Rabbit Eye.

Randolph D Glickman, Michael Onorato, Maria M Campos, Michael P O'Boyle, Ratnesh K Singh, Thomas I Zarembinski, Francois Binette, Igor O Nasonkin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Randolph D GlickmanDepartment of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Michael OnoratoLineage Cell Therapeutics, Inc., Alameda, California, USA.
Maria M CamposHistopathology Core, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Michael P O'BoyleResearch Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Ratnesh K SinghLineage Cell Therapeutics, Inc., Alameda, California, USA.
Thomas I ZarembinskiLineage Cell Therapeutics, Inc., Alameda, California, USA.
Francois BinetteLineage Cell Therapeutics, Inc., Alameda, California, USA.
Igor O NasonkinLineage Cell Therapeutics, Inc., Alameda, California, USA.
Lineage Cell Therapeutics (United States) · USThe University of Texas Health Science Center at San Antonio · USNational Eye Institute · US

Funding

Histopathology CoreZICEY000461 · NEI · NATIONAL EYE INSTITUTE · PI SCHNEEWEIS, DAVID · 2009 to 2022
$7.7M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBiocompatible MaterialsDrug ToleranceEyeFemaleHydrogelsInjections, IntraocularRabbitsBiocompatible MaterialsHydrogelselectroretinographyhydrogelHyStemintraocular injectionOCTtoxicity

Identifiers

PMID33449859
PMCPMC8020505
OpenAlexW3125403575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.